It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment discontinuation due to toxicity compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
S‐1 showed no clear difference in overall Survival compared with 5‐FU‐containing regimens (high certainty).
It is very uncertain whether S‐1 changes tumour response compared with 5‐FU‐containing regimens (very low certainty).
S‐1 showed no clear difference in progression‐free survival compared with 5‐FU‐containing regimens (low certainty).
S‐1 showed no clear difference in time‐to treatment failure compared with 5‐FU‐containing regimens (low certainty).
Combination showed no clear difference in treatment‐related death compared with single‐agent chemotherapy (moderate certainty).
S‐1 showed no clear difference in treatment‐related deaths compared with 5‐FU‐containing regimens (moderate certainty).
S‐1 showed no clear difference in treatment discontinuation due to toxicity compared with 5‐FU‐containing regimens (high certainty).
5‐FU/cisplatin/anthracycline combinations probably leads to lower overall survival compared with 5‐FU/cisplatin combinations (without anthracyclines) (moderate certainty).
5‐FU/cisplatin/anthracycline combinations may leads to higher tumour response compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).
5‐FU/cisplatin/anthracycline combinations may leads to lower time to progression compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).
Laparoscopic gastrectomy showed no clear difference in short‐term mortality compared with open gastrectomy (low certainty).
It is very uncertain whether laparoscopic gastrectomy changes long‐term mortality (maximal compared with open gastrectomy (very low certainty).
It is very uncertain whether laparoscopic gastrectomy changes proportion with a serious adverse event (< 3 months) compared with open gastrectomy (very low certainty).
It is very uncertain whether laparoscopic gastrectomy changes long‐term recurrence (maximal compared with open gastrectomy (very low certainty).
It is very uncertain whether laparoscopic gastrectomy changes proportion with an adverse event (< 3 months) compared with open gastrectomy (very low certainty).
Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).